Report cover image

Hydroxychloroquine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Dec 01, 2024
Length 120 Pages
SKU # FOB19410732

Description

Hydroxychloroquine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Hydroxychloroquine Market

The hydroxychloroquine market size was valued at USD 894.0 million in 2019, and the market is now projected to grow USD 2799.0 million in 2032 exhibiting a CAGR of 4.7% during the forecast period of 2020-2032.

The hydroxychlorolture market was affected by COVID-19 because of increased use as treatment for the virus despite having unproven efficacy. Then, shortages in supply and the rising prices became apparent, putting a pressure on the international markets. It was later that research began to cast doubts on its effectiveness and safety for COVID-19 and thus the market demand normalizes. It underlined how exactly the treatment of a pandemic is a complex process that requires the evidence of the experimented solutions.

As of April 2020, WHO confirmed itself 2 million active COVID-19 cases and 126,758 deaths; the virus was defined as pandemic by the same organization in March 2020. Due to lack of direct treatment and vaccine, which was projected to be available for more than 18 months, health caring authority endorsed other agents for controlling of the disease. This effort also had a potential candidate in hydroxychloroquine as a measure of disease control.

Hydroxychloroquine manufacturers around the world increased production during the COVID-19 pandemic based on favorable findings in France and the U.S. in which it was trailed in a small number of patients. This led to high volume importation of the virus by countries such as the U.S. as a measure of control. As a result, the depict growth in demand made manufactures in the industry to scale up their outputs uniquely this explained the high levels of capacity utilization.

Comprehensive Analysis of Hydroxychloroquine Market

The hydroxychloroquine market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly provides a thorough market breakdown near to the industry considering the leading supply and demand forces. These segmentations are methodically segregated by disease indication analysis and by distribution channel analysis. By disease indication analysis include malaria, COVID-19, rheumatoid arthritis, and others. By distribution channel analysis include hospital pharmacy, retail pharmacy, and online pharmacy.

The Asia Pacific region lead the hydroxychloroquine market share by benefitting a market size of USD 3346.9 million in 2018 due to Increasing use of the drug in treating malaria.

The top players in the markets have a central responsibility in the healthcare industry to be sure of industrial prospectus development and to establish the market norms. These players include, Sanofi, Zydus Cadila, Ipca Laboratories Ltd, Sandoz International GmbH (part of Novartis AG), Mylan N.V., Teva Pharmaceutical Industries Ltd, Bayer AG these market players provide a level-playing competitive landscape.

In June 2021, Catalent, Inc. announced the acquisition of RheinCell Therapeutics GmbH to enhance its stem cell therapy process development and manufacturing capabilities.

Segmentation Table

ATTRIBUTE DETAILS

Study Period2016-2027

Base Year2019

Forecast Period2020-2027

Historical Period2016-2018

UnitValue (USD million)

SegmentationBy Disease Indications

Malaria

COVID-19

Rheumatoid Arthritis

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Stores

By Geography

North America (the U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East& Africa (South Africa, GCC and Rest of Middle East & Africa)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

120 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Epidemiology of Malaria, Key Regions
4.2. Key development in Hydroxychloroquine Market
4.3. Impact of COVID-19 Outbreak
4.4. Pipeline Analysis
5. Global Hydroxychloroquine Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Disease Indication
5.2.1. Malaria
5.2.2. COVID-19
5.2.3. Rheumatoid Arthritis
5.2.4. Others
5.3. Market Analysis, Insights and Forecast – By Distribution Channels
5.3.1. Hospital Pharmacy
5.3.2. Retail Pharmacy
5.3.3. Online Pharmacy
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Latin America
5.4.5. Middle East & Africa
6. North America Hydroxychloroquine Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis – By Disease Indication
6.2.1. Malaria
6.2.2. COVID-19
6.2.3. Rheumatoid Arthritis
6.2.4. Others
6.3. Market Analysis – By Distribution Channels
6.3.1. Hospital Pharmacy
6.3.2. Retail Pharmacy
6.3.3. Online Pharmacy
6.4. Market Analysis – By Country
6.4.1. U.S.
6.4.2. Canada
7. Europe Hydroxychloroquine Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis – By Disease Indication
7.2.1. Malaria
7.2.2. COVID-19
7.2.3. Rheumatoid Arthritis
7.2.4. Others
7.3. Market Analysis – By Distribution Channels
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Market Analysis – By Country/Sub-region
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Spain
7.4.5. Italy
7.4.6. Scandinavia
7.4.7. Rest of Europe
8. Asia Pacific Hydroxychloroquine Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis – By Disease Indication
8.2.1. Malaria
8.2.2. COVID-19
8.2.3. Rheumatoid Arthritis
8.2.4. Others
8.3. Market Analysis – By Distribution Channels
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Analysis – By Country/Sub-region
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. Southeast Asia
8.4.6. Rest of Asia Pacific
9. Latin America Hydroxychloroquine Market Analysis, Insights and Forecast, 2016-2027
9.1. Key Findings / Summary
9.2. Market Analysis – By Disease Indication
9.2.1. Malaria
9.2.2. COVID-19
9.2.3. Rheumatoid Arthritis
9.2.4. Others
9.3. Market Analysis – By Distribution Channels
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Analysis – By Country/Sub-region
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
10. Middle East & Africa Hydroxychloroquine Market Analysis, Insights and Forecast, 2016-2027
10.1. Key Findings / Summary
10.2. Market Analysis – By Disease Indication
10.2.1. Malaria
10.2.2. COVID-19
10.2.3. Rheumatoid Arthritis
10.2.4. Others
10.3. Market Analysis – By Distribution Channels
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Market Analysis – By Country/Sub-region
10.4.1. GCC Countries
10.4.2. South Africa
10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2019)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles
11.5.1. Sanofi
11.5.1.1. Overview,
11.5.1.2. Products & services,
11.5.1.3. SWOT analysis,
11.5.1.4. Recent developments,
11.5.1.5. strategies,
11.5.1.6. financials (based on availability)
11.5.2. Zydus Cadia
11.5.2.1. Overview,
11.5.2.2. Products & services,
11.5.2.3. SWOT analysis,
11.5.2.4. Recent developments,
11.5.2.5. strategies,
11.5.2.6. financials (based on availability)
11.5.3. Ipca Laboratories Ltd
11.5.3.1. Overview,
11.5.3.2. Products & services,
11.5.3.3. SWOT analysis,
11.5.3.4. Recent developments,
11.5.3.5. strategies,
11.5.3.6. financials (based on availability)
11.5.4. Sandoz International GmbH (part of Novartis AG)
11.5.4.1. Overview,
11.5.4.2. Products & services,
11.5.4.3. SWOT analysis,
11.5.4.4. Recent developments,
11.5.4.5. strategies,
11.5.4.6. financials (based on availability)
11.5.5. Mylan N.V.
11.5.5.1. Overview,
11.5.5.2. Products & services,
11.5.5.3. SWOT analysis,
11.5.5.4. Recent developments,
11.5.5.5. strategies,
11.5.5.6. financials (based on availability)
11.5.6. Teva Pharmaceutical Industries Ltd
11.5.6.1. Overview,
11.5.6.2. Products & services,
11.5.6.3. SWOT analysis,
11.5.6.4. Recent developments,
11.5.6.5. strategies,
11.5.6.6. financials (based on availability)
11.5.7. Bayer AG
11.5.7.1. Overview,
11.5.7.2. Products & services,
11.5.7.3. SWOT analysis,
11.5.7.4. Recent developments,
11.5.7.5. strategies,
11.5.7.6. financials (based on availability)
11.5.8. Other Prominent Players
11.5.8.1. Overview,
11.5.8.2. Products & services,
11.5.8.3. SWOT analysis,
11.5.8.4. Recent developments,
11.5.8.5. strategies,
11.5.8.6. financials (based on availability)
12. Strategic Recommendations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us